三元生物(301206) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥272,598,107.02, representing a 3.46% increase compared to ¥263,493,075.06 in the same period last year[3] - Net profit attributable to shareholders decreased by 9.64% to ¥62,765,994.16 from ¥69,465,064.33 year-on-year[3] - Basic and diluted earnings per share fell by 26.09% to ¥0.51 from ¥0.69 in the same period last year[3] - Total operating revenue for Q1 2022 was CNY 272,598,107.02, an increase from CNY 263,493,075.06 in the previous period[20] - Net profit for Q1 2022 was CNY 62,765,994.16, down from CNY 69,465,064.33 in the previous period, indicating a decrease of approximately 9.7%[21] - Earnings per share for Q1 2022 were CNY 0.51, compared to CNY 0.69 in the previous period, showing a decline[22] Cash Flow - The net cash flow from operating activities dropped significantly by 84.24% to ¥20,443,976.73, down from ¥129,686,530.82 in the previous year[3] - The net cash flow from operating activities for Q1 2022 was ¥20,443,976.73, a decrease of 84.25% compared to ¥129,686,530.82 in Q1 2021[25] - Total cash inflow from financing activities was ¥3,573,401,313.01, while cash outflow was ¥22,336,495.47, resulting in a net cash flow of ¥3,551,064,817.54[26] - The net increase in cash and cash equivalents for the period was ¥9,191,788.52, compared to an increase of ¥83,423,153.69 in the previous year[26] - The total cash and cash equivalents at the end of the period stood at ¥267,134,010.23, up from ¥141,186,753.95 at the end of Q1 2021[26] - The company reported cash inflow from operating activities totaling ¥312,922,891.80, an increase from ¥290,470,739.70 in the same period last year[25] - Cash outflow for purchasing goods and services was ¥266,221,244.95, significantly higher than ¥139,392,617.05 in Q1 2021[25] - The company recorded cash inflow from investment activities of ¥477,900.00, while cash outflow was ¥3,563,181,945.45, leading to a net cash flow of -¥3,562,704,045.45[25] - The company received ¥3,567,762,730.40 from investment activities, indicating strong capital inflow during the quarter[26] Assets and Liabilities - Total assets increased by 213.32% to ¥5,120,094,004.66 compared to ¥1,634,157,434.85 at the end of the previous year[3] - Total liabilities for Q1 2022 were CNY 465,185,884.07, down from CNY 588,828,870.18 in the previous period[18] - The company's equity attributable to shareholders was CNY 4,654,908,120.59, significantly higher than CNY 1,045,328,564.67 in the previous period[18] - Deferred income tax liabilities increased to CNY 25,228,040.35 from CNY 23,025,951.67 in the previous period[18] Shareholder Information - Total number of common shareholders at the end of the reporting period is 21.906 million[11] - The largest shareholder, Nie Zaijian, holds 45.94% of shares, totaling 61,964,000 shares[11] Investment and Subsidiary Activities - The company raised a total of RMB 3,685,705,300 from the public offering of 33.721 million shares at RMB 109.3 per share[13] - The net amount raised after deducting issuance costs was RMB 3,546,644,640.40[13] - The company established a wholly-owned subsidiary, Sanyuan Biological Engineering Research (Tianjin) Co., Ltd., with an investment of RMB 5 million[14] Other Financial Metrics - Cash received from tax refunds increased by 47.42%, primarily due to an increase in VAT refunds during the reporting period[8] - The company experienced a 90.99% increase in cash paid for purchasing goods and services, attributed to rising raw material prices and a shift in payment methods[8] - Other payables increased by 44.69%, mainly due to an increase in customer deposits for yeast mud sales[9] - Research and development expenses for Q1 2022 were CNY 10,219,983.55, slightly down from CNY 11,579,638.16 in the previous period[21] Audit Status - The report for Q1 2022 was not audited, which may affect the reliability of the financial data presented[27]